FimmCyte and Richter Collaborate on Endometriosis Breakthrough – Startupticker.ch
Startupticker.ch shared a post on LinkedIn։
“FimmCyte, a femtech company developing new treatments for endometriosis, has entered into a research collaboration and option-to-license agreement with Richter, a leading Hungarian pharmaceutical company, to advance research on its lead clinical candidate, FMC2. The parties have fully negotiated a definitive, exclusive and worldwide license agreement for the future development and commercialization of the antibody. FimmCyte will be eligible to receive development and commercial milestone payments, together with tiered royalties on net sales, as provided under the pre-agreed license agreement.
More about FimmCyte, its clinical candidate and the collaboration in our article․”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 14, 2026, 15:14This Month’s F and S On Air Podcast Is Out Now – Fertility and Sterility
-
Apr 14, 2026, 14:51Lydia Akpan: Key Signs of Oocyte Dysmorphism
-
Apr 14, 2026, 14:42Emre Göksan Pabuçcu: Honored to Speak at the 12th National Gynecological Endoscopy Congress
-
Apr 14, 2026, 14:36Shivam Rathore: Why Temperature and Humidity Control in IVF Labs is Non-Negotiable?
-
Apr 14, 2026, 14:29Yannick Hurni: Attending SEUD 2026 Has Been a Powerful Reminder of What Conferences Truly Represent
-
Apr 14, 2026, 14:26Maria Cristina Sangiovanni: Honored to Have Spoken at the 12th SEUD Congress in Frankfurt!
-
Apr 14, 2026, 14:21Nikolaos Polyzos: What Will Reproductive Medicine Look Like in 10 Years?
-
Apr 14, 2026, 14:16Xavier Carcopino: Early and Organized HPV Vaccination Saves Lives
-
Apr 14, 2026, 12:52Ting Yuan: Using Endometrial Immune Profiling in Young IVF Patients